3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 74, n° 6
page 1073 (juin 2016)
Doi : 10.1016/j.jaad.2015.11.024
accepted : 9 November 2015
Original Articles

Assessing the clinical effectiveness of an algorithmic approach for mucosal lichen planus (MLP): A retrospective review

Kurt A. Ashack, MHS, BA a, Laura L. Haley, BS a, Chelsea A. Luther, BS a, Christie A. Riemer, BS a, Richard J. Ashack, MD, MS a, b,
a Michigan State University College of Human Medicine, Grand Rapids, Michigan 
b Dermatology Associates of West Michigan, Grand Rapids, Michigan 

Reprint requests: Richard J. Ashack, MD, MS, Dermatology Associates of West Michigan, 655 Kenmoor SE, Suite 200, Grand Rapids, MI 49546.Dermatology Associates of West Michigan655 Kenmoor SE, Suite 200Grand RapidsMI49546

Mucosal lichen planus (MLP) is a therapeutic challenge in need of a new treatment approach because of its debilitating effect on patient's quality of life.


We sought to evaluate a standardized treatment plan for patients with MLP. A second objective was to describe the effect of mycophenolate mofetil in this patient population.


The study retrospectively analyzed 53 patients with MLP treated using a standardized algorithm. The number of MLP lesions, disease activity, and pain at the last visit were compared with baseline scores determined at the initial visit. Results were analyzed using the paired samples t test and confirmed with the Wilcoxon matched pairs signed rank test.


The average number of lesions was reduced from 3.77 to 1.67 (P  < .001). The average disease activity was reduced from 2.73 to 0.90 (P  < .001). Average pain reported decreased from 2.03 to 1.03 (P  < .001).


This study was a retrospective analysis of a small patient population. There was no universal symptom severity scale used at the time of treatment for some patients.


The standardized treatment plan reduced symptoms for patients with MLP. Mycophenolate mofetil appears to be a reasonable treatment option for these patients.

The full text of this article is available in PDF format.

Key words : autoimmune disorder, mucosal lichen planus, mycophenolate mofetil, oral lichen planus, treatment algorithm, vaginal lichen planus

 Funding sources: None.
 Conflicts of interest: None declared.

© 2016  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline